Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice

Pharmaceutical Research

Volumn 30, Issue 6, 2013, Pages 1553-1560

  Kijanka, Grzegorz ^a   Jiskoot, Wim ^b   Schellekens, Huub ^a,c   Brinks, Vera ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

animal study; anti drug antibodies; immunogenicity; interferon beta; therapy related factors

Indexed keywords

BETA1A INTERFERON; DRUG ANTIBODY; INTERFERON BETA SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; DRUG ADMINISTRATION ROUTES; HUMANS; IMMUNE TOLERANCE; INTERFERON-BETA; MICE, TRANSGENIC; MULTIPLE SCLEROSIS;

EID: 84877772279     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-0992-9     Document Type: Article

References (25)

1. Paty D, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):662-7.
2. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 1999;52(6):1239-43.
3. Bertolotto A, Gilli F, Sala A, Malucchi S, Milano E, Melis F, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology. 2003;60(4):634-9.
4. Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000;48(5):706-12.
5. Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P. Immunogenicity of interferon beta: differences among products. J Neurol. 2004;251(Supl 2):II15-24.
6. Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H. Development of a transgenic mouse model immune tolerant for human interferon Beta. Pharm Res. 2005;22(6):847-51.
7. Van Beers M, Jiskoot W, Schellekens H. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):767-75.
8. Hartung H, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, et al. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J Neurol. 2007;254(7):827-37.
9. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res. 1998;15(4):641-9.
10. Sorensen P. Neutralizing antibodies against interferon-beta. Ther Adv Neurol Disord. 2008;1(2):62-8.
11. Bendtzen K. Critical Review: assessment of interferon-β immunogenicity in multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):759-66.
12. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology. 1999;53(4):679-686.
13. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, et al. European IFNbeta-1a (Avonex) dose-comparison study investigators. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology. 2002;59(10):1507-17.
14. Freedman M, Francis GS, Sanders EA, Rice GP, O'Connor P, Comi G, et al. Once Weekly Interferon beta-1alpha for Multiple Sclerosis Study Group; University of British Columbia MS/MRI Research Group. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler. 2005;11(1):41-5.
15. Cohen B, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010;26(8):827-38.
16. van Beers M, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, et al. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods. 2010;352(1-2):32-7.
17. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20 Suppl 6:vi3-9.
18. Singh S. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100(2):357-87.
19. Barbosa M, Celis E. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discov Today. 2007;12(15-16):674-81.
20. Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw. 2001;12(1):56-61.
21. Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice. Pharm Res. 1997;14(10):1472-8.
22. Schellekens H, Jiskoot W. Erythropoietin-Associated PRCA: still an unsolved mystery. J Immunotoxicol. 2006;3(3):123-30.
23. Administration. FaD. Adalimumab. 2002. Pharmacology Reviews: Adalimumab product approval information - licensing action.; 2002 December 31. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2008/125057s110TOC.cfm
24. Peng A, Kosloski M, Nakamura G, Ding H, Balu-Iyer SV. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetic and immunogenicity in hemophilia A mice. AAPS J. 2011;14(1):35-42.
25. Van Regenmortel M, Boven K, Bader F. Immunogenicity of biopharmaceuticals: an example from erythropoietin. BioPharm Int. 2005;18(8):36-52.